Oasmia is a specialty pharmaceutical company dedicated to improving the lives of patients by enhancing the intravenous delivery of established and novel drugs in significant diseases, in several indications, including cancer.
Regulatory March 1, 2021Oasmia acquires global development and commercialization rights for Cantrixil, a clinical stage, ovarian cancer program
Regulatory February 19, 2021Year-end report for the shortened financial year May 1, 2020 – December 31, 2020
Non Regulatory February 16, 2021Invitation to presentation of Oasmia’s Year-end report on February 19
Oasmia Pharmaceutical published its Year-end report for the shortened financial year May 1, 2020 – December 31, 2020 on February 19, 2021, at 08.00 am CET. The company held a conference call and an online presentation on the same day at 10.00 am CET.